placebo gel (Washington University School of Medicine)

A poloxamer-based thermosensitive placebo gel developed by Washington University School of Medicine for use as a control in clinical trials for hereditary hemorrhagic telangiectasia (HHT). The formulation is composed of a combination of poloxamer 188 and 407, with the pH adjusted to a range of 4.5-6.5, and contains no active pharmacological ingredients. Designed for intranasal administration, the gel is thermosensitive, meaning it hardens upon application to the nasal mucosa and subsequently dissolves over a period of approximately 12 hours. In a Phase 2 double-blind, randomized controlled trial (NCT03519386), this placebo gel demonstrated significant clinical efficacy in reducing the severity of HHT-associated epistaxis (nosebleeds), likely due to its physical properties providing a protective barrier and moisturizing effect on fragile nasal telangiectasias.

Other names

placebo gel-Washington University School of Medicine-hereditary hemorrhagic telangiectasiaPlacebo thermosensitive gelPoloxamer placebo gelIntranasal placebo gel